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Meropenem: continuous or extended
infusion?
Frédéric Frippiat1,2*, Christelle Vercheval3 and Nathalie Layios4
To the Editor
We read with interest the article by Benitez-Cano and
colleagues about intrapulmonary concentrations of mer-
openem administered by continuous infusion (CI) in
critically ill patients with nosocomial pneumonia and
would like to make some comments [1].
Firstly, the pharmacokinetic/pharmacodynamic (PK/PD)
target was a free epithelial lining fluid (ELF) concentration
of 50% of time above MIC (50% fT >MIC). In our opinion,
a PK/PD target of 100% fT >MIC was more suitable, since
the study was performed under CI. Indeed, despite the fact
that the authors stated that “a precise estimate of the
concentration-time profile in ELF was not possible be-
cause all ELF samples were obtained at the same time,” CI
of β-lactams allows reasonably a 24/24 stable concentra-
tion both in plasma and ELF, as illustrated in the figures 2
and 6 for the plasma and ELF, respectively [1], and as
shown in other studies [2, 3].
Secondly, considering a target of 50% fT >MIC, similar
results were obtained with both extended infusion (EI)
over 4 h and CI (i.e., MIC up to 1 and up to 2mg/L for
both modes of infusion with 1 g/8 h and 2 g/8 h, respect-
ively), which are close to our results with EI over 3 h (i.e.,
MICS up to 0.5 and up to 1mg/L with 1 g/8 h and 2 g/8 h,
respectively) [4]. Thus, CI does not offer significant PK/
PD advantages over EI for meropenem. On a practical
point of view, CI of meropenem needs a dedicated intra-
venous line access (which is not always obvious in critic-
ally ill patients) and frequent infusion syringes changes
(every 5–8 h) due to stability issues, particularly at temper-
atures ≥ 25 °C [5].
Thirdly, studies performed in critically ill patients with
nosocomial pneumonia showed a high interindividual
variability in the β-lactams concentrations in ELF what-
ever the mode of infusion [1–4]. We agree with Benitez-
Cano et al. that even the highest dosage of meropenem
(2 g/8 h) administered by either CI or EI could not result
in an optimal ELF target attainment for a substantial
fraction of the population, particularly in patients with
augmented renal clearance.
In conclusion, when meropenem is considered as the
initial empiric antibiotic therapy for nosocomial pneu-
monia in critically ill patients, we strongly recommend
the dosage of 2 g/8 h by EI over 3 h (or by CI if the cart-
ridge is changed every 5–8 h and the temperature re-





I declare that all authors contributed equally to the redaction of this
manuscript. The authors read and approved the final manuscript.
Funding
None
Availability of data and materials
Not applicable







1Division of Infectious Diseases, Department of Internal Medicine, University
Hospital of Liège, Liège, Belgium. 2Service de Maladies Infectieuses, CHU de
Liège, Avenue de l’hôpital, 1 - B35, Sart Tilman, 4000 Liège, Belgium.
3Department of Clinical Pharmacy, University Hospital of Liège, Liège,
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: f.frippiat@chuliege.be
1Division of Infectious Diseases, Department of Internal Medicine, University
Hospital of Liège, Liège, Belgium
2Service de Maladies Infectieuses, CHU de Liège, Avenue de l’hôpital, 1 - B35,
Sart Tilman, 4000 Liège, Belgium
Full list of author information is available at the end of the article
Frippiat et al. Critical Care          (2020) 24:192 
https://doi.org/10.1186/s13054-020-02883-w
Belgium. 4Department of Intensive Care Unit, University Hospital of Liège,
Liège, Belgium.
Received: 18 March 2020 Accepted: 8 April 2020
References
1. Benítez-Cano A, Luque S, Sorlí L, Carazo J, Ramos I, Campillo N, Curull V,
Sánchez-Font A, Vilaplana C, Horcajada JP, Adalia R, Bermejo S, Samsó E,
Hope W, Grau S. Intrapulmonary concentrations of meropenem
administered by continuous infusion in critically ill patients with nosocomial
pneumonia: a randomized pharmacokinetic trial. Crit Care. 2020;24:55.
2. Boselli E, Breilh D, Rimmelé T, Guillaume C, Xuereb F, Saux MC, Bouvet L,
Chassard D, Allaouchiche B. Alveolar concentrations of piperacillin/
tazobactam administered in continuous infusion to patients with ventilator-
associated pneumonia. Crit Care Med. 2008;36:1500–6.
3. Heffernan AJ, Sime FB, Lipman J, Dhanani J, Andrews K, Ellwood D,
Grimwood K, Roberts JA. Intrapulmonary pharmacokinetics of antibiotics
used to treat nosocomial pneumonia caused by Gram-negative bacilli: a
systematic review. Int J Antimicrob Agents. 2019;53:234–45.
4. Frippiat F, Musuamba FT, Seidel L, Albert A, Denooz R, Charlier C, Van
Bambeke F, Wallemacq P, Descy J, Lambermont B, Layios N, Damas P,
Moutschen M. Modelled target attainment after meropenem infusion in
patients with severe nosocomial pneumonia: the PROMESSE study. J
Antimicrob Chemother. 2015;70:207–16.
5. Delattre IK, Briquet C, Wallemacq P, Tulkens PM, Van Bambeke F.
Comparative in vitro antimicrobial potency, stability, colouration and
dissolution time of generics versus innovator of meropenem in Europe. Int J
Antimicrob Agents. 2020;55:105825.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Frippiat et al. Critical Care          (2020) 24:192 Page 2 of 2
